| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 104 | 2023 | 1074 | 13.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 89 | 2022 | 1085 | 11.070 |
Why?
|
| Insulin Resistance | 68 | 2021 | 241 | 9.410 |
Why?
|
| Insulin | 70 | 2022 | 617 | 6.220 |
Why?
|
| Overweight | 24 | 2023 | 186 | 6.120 |
Why?
|
| Weight Loss | 31 | 2022 | 319 | 5.550 |
Why?
|
| Anti-Obesity Agents | 16 | 2023 | 42 | 4.870 |
Why?
|
| Cardiovascular Diseases | 22 | 2022 | 938 | 4.810 |
Why?
|
| Glucose | 40 | 2022 | 307 | 4.590 |
Why?
|
| Blood Glucose | 53 | 2022 | 631 | 4.510 |
Why?
|
| Metabolic Syndrome | 16 | 2021 | 191 | 4.170 |
Why?
|
| Endocrinology | 11 | 2022 | 16 | 3.690 |
Why?
|
| Phentermine | 8 | 2018 | 17 | 2.780 |
Why?
|
| Muscle, Skeletal | 19 | 2021 | 396 | 2.770 |
Why?
|
| Adiposity | 13 | 2021 | 88 | 2.730 |
Why?
|
| Monosaccharide Transport Proteins | 30 | 2005 | 54 | 2.670 |
Why?
|
| Fructose | 6 | 2017 | 51 | 2.450 |
Why?
|
| Adiponectin | 11 | 2018 | 52 | 2.440 |
Why?
|
| Life Style | 15 | 2021 | 338 | 2.430 |
Why?
|
| Adipocytes | 11 | 2016 | 88 | 2.390 |
Why?
|
| Humans | 230 | 2023 | 68549 | 2.350 |
Why?
|
| Hypoglycemic Agents | 18 | 2022 | 361 | 2.050 |
Why?
|
| Prediabetic State | 12 | 2019 | 48 | 2.050 |
Why?
|
| Body Mass Index | 26 | 2023 | 866 | 2.050 |
Why?
|
| Endocrinologists | 9 | 2020 | 12 | 2.020 |
Why?
|
| Adipose Tissue | 31 | 2020 | 221 | 2.000 |
Why?
|
| Muscle Proteins | 17 | 2010 | 94 | 1.990 |
Why?
|
| Energy Metabolism | 12 | 2017 | 222 | 1.950 |
Why?
|
| Weight Reduction Programs | 6 | 2023 | 67 | 1.870 |
Why?
|
| Adult | 108 | 2023 | 21379 | 1.820 |
Why?
|
| Male | 140 | 2023 | 37283 | 1.760 |
Why?
|
| Leptin | 6 | 2020 | 80 | 1.640 |
Why?
|
| Middle Aged | 82 | 2023 | 21119 | 1.560 |
Why?
|
| Lipid Metabolism | 12 | 2015 | 186 | 1.550 |
Why?
|
| Female | 123 | 2023 | 38021 | 1.540 |
Why?
|
| Receptors, Steroid | 5 | 2016 | 13 | 1.420 |
Why?
|
| Lipoproteins | 12 | 2015 | 161 | 1.300 |
Why?
|
| Cholesterol | 13 | 2023 | 331 | 1.240 |
Why?
|
| Polymorphism, Genetic | 14 | 2011 | 301 | 1.200 |
Why?
|
| Glucose Tolerance Test | 15 | 2016 | 75 | 1.180 |
Why?
|
| Adipokines | 2 | 2017 | 20 | 1.180 |
Why?
|
| Foam Cells | 8 | 2015 | 26 | 1.170 |
Why?
|
| Diabetes Mellitus | 17 | 2022 | 694 | 1.130 |
Why?
|
| Bariatric Surgery | 7 | 2019 | 90 | 1.120 |
Why?
|
| Lipids | 14 | 2022 | 298 | 1.110 |
Why?
|
| Carrier Proteins | 13 | 2013 | 597 | 1.110 |
Why?
|
| Cell Cycle Proteins | 3 | 2021 | 230 | 1.100 |
Why?
|
| DNA-Binding Proteins | 6 | 2016 | 700 | 1.100 |
Why?
|
| United States | 32 | 2023 | 7338 | 1.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 17 | 2021 | 529 | 1.070 |
Why?
|
| Liraglutide | 3 | 2022 | 18 | 1.050 |
Why?
|
| Glucagon-Like Peptides | 6 | 2022 | 15 | 1.050 |
Why?
|
| Body Weight | 16 | 2023 | 554 | 1.030 |
Why?
|
| Body Composition | 12 | 2020 | 119 | 1.020 |
Why?
|
| Hyperglycemia | 5 | 2017 | 158 | 1.020 |
Why?
|
| Receptors, Thyroid Hormone | 2 | 2016 | 4 | 1.020 |
Why?
|
| Double-Blind Method | 17 | 2022 | 1738 | 1.010 |
Why?
|
| Eating | 3 | 2023 | 119 | 0.990 |
Why?
|
| Animals | 65 | 2023 | 20880 | 0.940 |
Why?
|
| Glucose Intolerance | 8 | 2020 | 36 | 0.930 |
Why?
|
| Chronic Disease | 8 | 2022 | 1329 | 0.910 |
Why?
|
| Primary Health Care | 3 | 2022 | 702 | 0.900 |
Why?
|
| Muscles | 10 | 2008 | 158 | 0.900 |
Why?
|
| Practice Guidelines as Topic | 7 | 2016 | 772 | 0.890 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2013 | 20 | 0.850 |
Why?
|
| Gene Expression Regulation | 11 | 2014 | 1293 | 0.840 |
Why?
|
| Preventive Health Services | 2 | 2020 | 86 | 0.840 |
Why?
|
| Canagliflozin | 2 | 2020 | 3 | 0.820 |
Why?
|
| Benzazepines | 3 | 2018 | 104 | 0.820 |
Why?
|
| Mitochondrial Proteins | 9 | 2009 | 113 | 0.810 |
Why?
|
| Diabetes Mellitus, Experimental | 11 | 2021 | 195 | 0.810 |
Why?
|
| Drug Costs | 1 | 2022 | 87 | 0.810 |
Why?
|
| Societies, Medical | 7 | 2018 | 403 | 0.790 |
Why?
|
| Repressor Proteins | 3 | 2021 | 182 | 0.790 |
Why?
|
| Diet | 5 | 2016 | 514 | 0.770 |
Why?
|
| Vascular Stiffness | 1 | 2021 | 31 | 0.770 |
Why?
|
| Emotions | 1 | 2022 | 244 | 0.740 |
Why?
|
| Atherosclerosis | 7 | 2015 | 204 | 0.740 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2020 | 4 | 0.730 |
Why?
|
| Clinical Coding | 1 | 2020 | 21 | 0.730 |
Why?
|
| Sulfonylurea Compounds | 2 | 2018 | 17 | 0.730 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2020 | 1 | 0.720 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 445 | 0.710 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2020 | 37 | 0.710 |
Why?
|
| Algorithms | 11 | 2020 | 1195 | 0.710 |
Why?
|
| Waist Circumference | 3 | 2017 | 32 | 0.710 |
Why?
|
| Young Adult | 24 | 2022 | 5710 | 0.700 |
Why?
|
| Lipolysis | 4 | 2016 | 13 | 0.700 |
Why?
|
| Genotype | 10 | 2021 | 785 | 0.700 |
Why?
|
| Oxygen Consumption | 6 | 2019 | 258 | 0.690 |
Why?
|
| Energy Intake | 7 | 2021 | 123 | 0.690 |
Why?
|
| Mice | 26 | 2021 | 8474 | 0.680 |
Why?
|
| Rats | 31 | 2020 | 5300 | 0.680 |
Why?
|
| Health Care Costs | 1 | 2022 | 346 | 0.680 |
Why?
|
| Glucose Clamp Technique | 11 | 2021 | 24 | 0.680 |
Why?
|
| Hypogonadism | 1 | 2019 | 9 | 0.670 |
Why?
|
| Disease Progression | 7 | 2021 | 1037 | 0.660 |
Why?
|
| Glucose Transporter Type 4 | 18 | 2013 | 34 | 0.660 |
Why?
|
| Risk Factors | 22 | 2021 | 5720 | 0.660 |
Why?
|
| Amino Acids | 4 | 2019 | 131 | 0.650 |
Why?
|
| Testosterone | 1 | 2019 | 96 | 0.650 |
Why?
|
| Triglycerides | 11 | 2019 | 184 | 0.640 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 329 | 0.640 |
Why?
|
| Inflammation | 7 | 2018 | 1030 | 0.640 |
Why?
|
| Diet, Reducing | 4 | 2021 | 46 | 0.640 |
Why?
|
| Biological Transport | 16 | 2014 | 210 | 0.640 |
Why?
|
| Fasting | 5 | 2019 | 75 | 0.630 |
Why?
|
| Biomarkers | 11 | 2022 | 1593 | 0.620 |
Why?
|
| DNA, Mitochondrial | 5 | 2005 | 84 | 0.610 |
Why?
|
| Delayed-Action Preparations | 6 | 2017 | 120 | 0.610 |
Why?
|
| Fatty Acid-Binding Proteins | 4 | 2016 | 30 | 0.600 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 290 | 0.600 |
Why?
|
| Cells, Cultured | 23 | 2014 | 2673 | 0.590 |
Why?
|
| Lipoproteins, LDL | 12 | 2015 | 343 | 0.590 |
Why?
|
| Biological Specimen Banks | 1 | 2017 | 38 | 0.590 |
Why?
|
| Fatty Acids | 5 | 2019 | 222 | 0.590 |
Why?
|
| Mental Disorders | 1 | 2022 | 659 | 0.560 |
Why?
|
| Exercise | 6 | 2022 | 658 | 0.560 |
Why?
|
| Genome-Wide Association Study | 4 | 2017 | 240 | 0.560 |
Why?
|
| Inflammation Mediators | 2 | 2015 | 244 | 0.560 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2016 | 40 | 0.560 |
Why?
|
| Lipodystrophy | 2 | 2013 | 3 | 0.560 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2016 | 34 | 0.550 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2016 | 4 | 0.550 |
Why?
|
| Catecholamines | 1 | 2016 | 73 | 0.550 |
Why?
|
| Obesity, Metabolically Benign | 1 | 2015 | 1 | 0.540 |
Why?
|
| Epinephrine | 1 | 2016 | 103 | 0.540 |
Why?
|
| Membrane Transport Proteins | 3 | 2004 | 81 | 0.530 |
Why?
|
| Terminology as Topic | 1 | 2016 | 141 | 0.530 |
Why?
|
| Liver | 9 | 2021 | 1118 | 0.520 |
Why?
|
| Cross-Sectional Studies | 13 | 2023 | 2265 | 0.520 |
Why?
|
| Dairy Products | 1 | 2015 | 13 | 0.520 |
Why?
|
| MicroRNAs | 2 | 2018 | 447 | 0.520 |
Why?
|
| Environment | 1 | 2016 | 115 | 0.510 |
Why?
|
| Meat | 1 | 2015 | 34 | 0.510 |
Why?
|
| Veterans | 1 | 2023 | 904 | 0.510 |
Why?
|
| Aged | 21 | 2021 | 14842 | 0.500 |
Why?
|
| Hexosamines | 2 | 2013 | 10 | 0.500 |
Why?
|
| Gene Deletion | 1 | 2016 | 235 | 0.500 |
Why?
|
| Behavior Therapy | 6 | 2021 | 297 | 0.490 |
Why?
|
| Metabolism | 3 | 2016 | 12 | 0.490 |
Why?
|
| Carnitine | 2 | 2016 | 17 | 0.480 |
Why?
|
| Receptor, Insulin | 11 | 1998 | 71 | 0.480 |
Why?
|
| Cytokines | 3 | 2015 | 866 | 0.480 |
Why?
|
| Blood Pressure | 12 | 2022 | 1449 | 0.470 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 121 | 0.470 |
Why?
|
| Osteocalcin | 1 | 2014 | 37 | 0.470 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 2004 | 24 | 0.470 |
Why?
|
| Diet, High-Fat | 5 | 2020 | 81 | 0.470 |
Why?
|
| Registries | 3 | 2019 | 730 | 0.460 |
Why?
|
| Coronary Disease | 1 | 2015 | 358 | 0.460 |
Why?
|
| Mercaptopurine | 1 | 2013 | 9 | 0.460 |
Why?
|
| Antimetabolites | 1 | 2013 | 17 | 0.460 |
Why?
|
| Biosynthetic Pathways | 1 | 2013 | 15 | 0.460 |
Why?
|
| Signal Transduction | 8 | 2018 | 2689 | 0.450 |
Why?
|
| Gene Expression | 11 | 2012 | 770 | 0.450 |
Why?
|
| Magnetic Resonance Spectroscopy | 10 | 2015 | 346 | 0.440 |
Why?
|
| Prostaglandins A | 1 | 2012 | 1 | 0.440 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 3 | 1 | 2012 | 1 | 0.440 |
Why?
|
| Apolipoproteins | 3 | 2019 | 51 | 0.440 |
Why?
|
| Health Status | 1 | 2015 | 429 | 0.430 |
Why?
|
| Absorptiometry, Photon | 6 | 2016 | 83 | 0.430 |
Why?
|
| Ion Channels | 9 | 2009 | 72 | 0.430 |
Why?
|
| Treatment Outcome | 10 | 2022 | 7028 | 0.420 |
Why?
|
| Lipid Peroxidation | 1 | 2012 | 94 | 0.410 |
Why?
|
| Uncoupling Protein 3 | 8 | 2009 | 13 | 0.410 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2018 | 54 | 0.400 |
Why?
|
| Adolescent | 18 | 2022 | 8904 | 0.400 |
Why?
|
| Lipogenesis | 2 | 2014 | 9 | 0.400 |
Why?
|
| Fatty Acids, Nonesterified | 6 | 2016 | 48 | 0.400 |
Why?
|
| Diabetes, Gestational | 5 | 1997 | 81 | 0.400 |
Why?
|
| Proteins | 4 | 2001 | 473 | 0.390 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2020 | 2083 | 0.390 |
Why?
|
| Incidence | 4 | 2020 | 1582 | 0.390 |
Why?
|
| Diabetic Angiopathies | 7 | 2015 | 203 | 0.390 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 5 | 0.390 |
Why?
|
| Citric Acid Cycle | 2 | 2016 | 15 | 0.380 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2007 | 66 | 0.370 |
Why?
|
| Intra-Abdominal Fat | 2 | 2020 | 11 | 0.370 |
Why?
|
| Rest | 1 | 2010 | 78 | 0.370 |
Why?
|
| Hyperinsulinism | 3 | 2007 | 23 | 0.360 |
Why?
|
| RNA, Messenger | 14 | 2011 | 1663 | 0.360 |
Why?
|
| Promoter Regions, Genetic | 6 | 2016 | 614 | 0.350 |
Why?
|
| Transcription Factors | 5 | 2014 | 753 | 0.350 |
Why?
|
| Lipoproteins, HDL | 5 | 2012 | 113 | 0.350 |
Why?
|
| Cholesterol, LDL | 7 | 2016 | 161 | 0.350 |
Why?
|
| Mitochondria, Muscle | 3 | 2021 | 12 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 929 | 0.340 |
Why?
|
| Bayes Theorem | 2 | 2022 | 307 | 0.340 |
Why?
|
| Protein Kinases | 1 | 2009 | 122 | 0.340 |
Why?
|
| Genetics, Population | 3 | 2005 | 21 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2013 | 786 | 0.330 |
Why?
|
| Nutrition Surveys | 3 | 2016 | 204 | 0.330 |
Why?
|
| Receptors, Adiponectin | 3 | 2013 | 10 | 0.330 |
Why?
|
| Craving | 2 | 2023 | 200 | 0.320 |
Why?
|
| GTP-Binding Proteins | 3 | 1998 | 231 | 0.320 |
Why?
|
| Dyslipidemias | 2 | 2022 | 98 | 0.320 |
Why?
|
| Thiazolidinediones | 3 | 2006 | 76 | 0.320 |
Why?
|
| Heterozygote | 2 | 1999 | 174 | 0.320 |
Why?
|
| Hyperlipidemias | 3 | 2018 | 90 | 0.310 |
Why?
|
| Point Mutation | 2 | 1998 | 97 | 0.300 |
Why?
|
| Obesity, Morbid | 4 | 2017 | 172 | 0.300 |
Why?
|
| Oxylipins | 2 | 2020 | 3 | 0.300 |
Why?
|
| Antipsychotic Agents | 2 | 2008 | 247 | 0.300 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2021 | 17 | 0.300 |
Why?
|
| Macrophages, Peritoneal | 3 | 2013 | 67 | 0.290 |
Why?
|
| Cohort Studies | 11 | 2020 | 2356 | 0.290 |
Why?
|
| Metabolome | 2 | 2019 | 15 | 0.290 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 3256 | 0.290 |
Why?
|
| Cell Differentiation | 6 | 2012 | 1034 | 0.290 |
Why?
|
| TCF Transcription Factors | 1 | 2006 | 5 | 0.290 |
Why?
|
| Allylamine | 3 | 2011 | 3 | 0.290 |
Why?
|
| Reference Values | 7 | 2008 | 579 | 0.280 |
Why?
|
| Basal Metabolism | 2 | 2004 | 22 | 0.280 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2018 | 626 | 0.280 |
Why?
|
| Trans-Activators | 3 | 2014 | 237 | 0.280 |
Why?
|
| Anticholesteremic Agents | 3 | 2011 | 49 | 0.280 |
Why?
|
| Up-Regulation | 5 | 2021 | 682 | 0.270 |
Why?
|
| Haplotypes | 2 | 2005 | 174 | 0.270 |
Why?
|
| Reactive Oxygen Species | 3 | 2021 | 499 | 0.270 |
Why?
|
| Lentivirus | 4 | 2012 | 35 | 0.270 |
Why?
|
| Deoxyglucose | 7 | 1995 | 32 | 0.270 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1465 | 0.270 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2016 | 209 | 0.270 |
Why?
|
| Body Fat Distribution | 3 | 2013 | 8 | 0.270 |
Why?
|
| Diabetic Retinopathy | 4 | 2021 | 110 | 0.270 |
Why?
|
| C-Reactive Protein | 4 | 2018 | 180 | 0.270 |
Why?
|
| Retrospective Studies | 3 | 2023 | 7268 | 0.270 |
Why?
|
| Time Factors | 10 | 2015 | 4655 | 0.270 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 951 | 0.260 |
Why?
|
| Inheritance Patterns | 1 | 2005 | 7 | 0.260 |
Why?
|
| Genetic Heterogeneity | 1 | 2005 | 11 | 0.260 |
Why?
|
| Particle Size | 6 | 2014 | 201 | 0.260 |
Why?
|
| Diabetes Complications | 3 | 2019 | 249 | 0.260 |
Why?
|
| Comprehensive Health Care | 2 | 2015 | 26 | 0.250 |
Why?
|
| Subcellular Fractions | 4 | 2001 | 92 | 0.250 |
Why?
|
| Kinetics | 13 | 2006 | 1047 | 0.250 |
Why?
|
| Genetic Variation | 3 | 2017 | 220 | 0.250 |
Why?
|
| Pregnancy | 7 | 2022 | 2334 | 0.250 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2005 | 146 | 0.250 |
Why?
|
| Kidney Tubules, Proximal | 3 | 1994 | 81 | 0.250 |
Why?
|
| Thiazoles | 2 | 2002 | 95 | 0.250 |
Why?
|
| Aminopeptidases | 2 | 2001 | 6 | 0.240 |
Why?
|
| Mice, Knockout | 4 | 2017 | 1692 | 0.240 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 648 | 0.240 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1054 | 0.240 |
Why?
|
| Genome, Human | 2 | 2004 | 62 | 0.240 |
Why?
|
| Metformin | 2 | 2018 | 63 | 0.240 |
Why?
|
| Thermogenesis | 1 | 2004 | 5 | 0.240 |
Why?
|
| Social Determinants of Health | 2 | 2022 | 96 | 0.240 |
Why?
|
| Dietary Fats | 2 | 2020 | 103 | 0.240 |
Why?
|
| South Carolina | 9 | 2014 | 2752 | 0.230 |
Why?
|
| Mice, Transgenic | 7 | 2016 | 1033 | 0.230 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 791 | 0.230 |
Why?
|
| Quality of Life | 3 | 2017 | 1515 | 0.230 |
Why?
|
| Consensus | 7 | 2020 | 211 | 0.230 |
Why?
|
| Immune System | 1 | 2004 | 63 | 0.230 |
Why?
|
| Lipoproteins, VLDL | 4 | 2011 | 32 | 0.230 |
Why?
|
| Chromans | 2 | 2002 | 12 | 0.230 |
Why?
|
| Analysis of Variance | 7 | 2009 | 1040 | 0.230 |
Why?
|
| Cell Membrane | 12 | 1995 | 524 | 0.230 |
Why?
|
| Diabetic Nephropathies | 4 | 2008 | 161 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 6 | 1999 | 492 | 0.220 |
Why?
|
| Insulins | 1 | 2022 | 5 | 0.220 |
Why?
|
| Transfection | 4 | 2015 | 782 | 0.220 |
Why?
|
| Calorimetry, Indirect | 2 | 2016 | 12 | 0.220 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2018 | 84 | 0.220 |
Why?
|
| Down-Regulation | 5 | 2018 | 447 | 0.220 |
Why?
|
| Genomics | 1 | 2004 | 168 | 0.220 |
Why?
|
| Blotting, Western | 6 | 2016 | 954 | 0.210 |
Why?
|
| Sodium, Dietary | 1 | 2022 | 31 | 0.210 |
Why?
|
| Prunus dulcis | 1 | 2022 | 1 | 0.210 |
Why?
|
| Solanum tuberosum | 1 | 2022 | 1 | 0.210 |
Why?
|
| Molecular Weight | 5 | 2008 | 358 | 0.210 |
Why?
|
| Prednisone | 1 | 2002 | 104 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 8 | 2020 | 2791 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2013 | 627 | 0.210 |
Why?
|
| American Heart Association | 1 | 2023 | 142 | 0.210 |
Why?
|
| Perioperative Care | 2 | 2013 | 100 | 0.210 |
Why?
|
| Diet Therapy | 2 | 2022 | 22 | 0.210 |
Why?
|
| Gene Silencing | 2 | 2012 | 137 | 0.200 |
Why?
|
| Sex Characteristics | 4 | 2008 | 295 | 0.200 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2077 | 0.200 |
Why?
|
| Exercise Therapy | 2 | 2021 | 183 | 0.200 |
Why?
|
| Area Under Curve | 5 | 2014 | 238 | 0.200 |
Why?
|
| Albuminuria | 6 | 2013 | 171 | 0.200 |
Why?
|
| Birth Weight | 2 | 2020 | 186 | 0.200 |
Why?
|
| Uric Acid | 1 | 2021 | 37 | 0.190 |
Why?
|
| C-Peptide | 4 | 2008 | 23 | 0.190 |
Why?
|
| Glucocorticoids | 2 | 2002 | 222 | 0.190 |
Why?
|
| Bile Acids and Salts | 1 | 2021 | 19 | 0.190 |
Why?
|
| Alleles | 3 | 2012 | 386 | 0.190 |
Why?
|
| Cost of Illness | 1 | 2023 | 204 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 87 | 0.190 |
Why?
|
| Schools | 1 | 2022 | 156 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4843 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 503 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 503 | 0.190 |
Why?
|
| Least-Squares Analysis | 3 | 2014 | 35 | 0.190 |
Why?
|
| Intensive Care Units | 1 | 2023 | 344 | 0.180 |
Why?
|
| Weaning | 1 | 2020 | 12 | 0.180 |
Why?
|
| Bulimia | 1 | 2000 | 72 | 0.180 |
Why?
|
| Rats, Wistar | 3 | 2014 | 371 | 0.180 |
Why?
|
| Transduction, Genetic | 2 | 2012 | 81 | 0.180 |
Why?
|
| Longevity | 1 | 2020 | 59 | 0.180 |
Why?
|
| Glucose Transporter Type 1 | 5 | 2007 | 18 | 0.180 |
Why?
|
| Regression Analysis | 7 | 2018 | 737 | 0.180 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 1851 | 0.180 |
Why?
|
| Bariatrics | 1 | 2019 | 5 | 0.180 |
Why?
|
| Gastric Balloon | 1 | 2019 | 6 | 0.180 |
Why?
|
| Hunger | 1 | 2020 | 27 | 0.180 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 85 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1070 | 0.170 |
Why?
|
| Health Education | 1 | 2022 | 279 | 0.170 |
Why?
|
| Mental Health | 1 | 2022 | 278 | 0.170 |
Why?
|
| Deoxy Sugars | 3 | 1989 | 3 | 0.170 |
Why?
|
| Leadership | 1 | 2021 | 136 | 0.170 |
Why?
|
| Risk Assessment | 3 | 2015 | 2004 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 142 | 0.170 |
Why?
|
| Mutation | 4 | 1999 | 1213 | 0.170 |
Why?
|
| ras Proteins | 2 | 1997 | 102 | 0.170 |
Why?
|
| DNA | 3 | 2001 | 597 | 0.170 |
Why?
|
| Oxidation-Reduction | 4 | 2019 | 567 | 0.170 |
Why?
|
| Child | 6 | 2022 | 6401 | 0.170 |
Why?
|
| Lactation | 1 | 2020 | 110 | 0.170 |
Why?
|
| Retina | 1 | 2021 | 252 | 0.170 |
Why?
|
| Animals, Newborn | 1 | 2020 | 396 | 0.170 |
Why?
|
| Arabidopsis Proteins | 1 | 1998 | 13 | 0.170 |
Why?
|
| rab GTP-Binding Proteins | 1 | 1998 | 15 | 0.160 |
Why?
|
| Patient Education as Topic | 3 | 2018 | 424 | 0.160 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 1998 | 2 | 0.160 |
Why?
|
| Lecithin Cholesterol Acyltransferase Deficiency | 1 | 1998 | 2 | 0.160 |
Why?
|
| Gastric Bypass | 1 | 2019 | 83 | 0.160 |
Why?
|
| Indians, North American | 5 | 1998 | 64 | 0.160 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 154 | 0.160 |
Why?
|
| Placebos | 2 | 2022 | 195 | 0.160 |
Why?
|
| Sex Factors | 3 | 2021 | 1265 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2023 | 2455 | 0.160 |
Why?
|
| Dexamethasone | 2 | 1989 | 150 | 0.160 |
Why?
|
| Risk Reduction Behavior | 3 | 2015 | 174 | 0.160 |
Why?
|
| Molybdoferredoxin | 1 | 2018 | 1 | 0.160 |
Why?
|
| Retinoid X Receptors | 1 | 2018 | 26 | 0.160 |
Why?
|
| Glycogen Synthase | 2 | 1997 | 5 | 0.160 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 10 | 0.160 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 357 | 0.160 |
Why?
|
| Macrophages | 3 | 2008 | 647 | 0.160 |
Why?
|
| Naphthalenes | 1 | 2018 | 47 | 0.150 |
Why?
|
| Genetic Vectors | 3 | 2010 | 311 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1174 | 0.150 |
Why?
|
| Glycogen | 1 | 1997 | 27 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 1753 | 0.150 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 10 | 0.150 |
Why?
|
| Precision Medicine | 2 | 2016 | 111 | 0.150 |
Why?
|
| Genes | 2 | 1997 | 86 | 0.150 |
Why?
|
| Phenotype | 5 | 2017 | 946 | 0.150 |
Why?
|
| Counseling | 2 | 2018 | 279 | 0.150 |
Why?
|
| Physical Conditioning, Animal | 1 | 1997 | 34 | 0.150 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 2 | 2007 | 5 | 0.150 |
Why?
|
| Morbidity | 1 | 2017 | 130 | 0.150 |
Why?
|
| Oxidative Phosphorylation | 3 | 2016 | 54 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2019 | 237 | 0.150 |
Why?
|
| Obesity Management | 1 | 2017 | 2 | 0.150 |
Why?
|
| United Kingdom | 1 | 2017 | 152 | 0.150 |
Why?
|
| Global Health | 1 | 2017 | 135 | 0.150 |
Why?
|
| Psychosocial Support Systems | 1 | 2017 | 12 | 0.150 |
Why?
|
| 3-O-Methylglucose | 6 | 1995 | 6 | 0.150 |
Why?
|
| Methylglucosides | 6 | 1995 | 7 | 0.150 |
Why?
|
| GTP Phosphohydrolases | 1 | 1997 | 46 | 0.150 |
Why?
|
| Endostatins | 1 | 2017 | 11 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2021 | 413 | 0.140 |
Why?
|
| Neurons, Afferent | 1 | 2016 | 32 | 0.140 |
Why?
|
| Duodenum | 1 | 2016 | 47 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 34 | 0.140 |
Why?
|
| Patient Dropouts | 2 | 2022 | 98 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2007 | 65 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 84 | 0.140 |
Why?
|
| Mucous Membrane | 1 | 2016 | 66 | 0.140 |
Why?
|
| Dietary Carbohydrates | 2 | 2008 | 27 | 0.140 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 1851 | 0.140 |
Why?
|
| Uncoupling Protein 2 | 3 | 2004 | 18 | 0.140 |
Why?
|
| 3T3-L1 Cells | 2 | 2007 | 30 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 331 | 0.140 |
Why?
|
| Logistic Models | 1 | 2020 | 1419 | 0.140 |
Why?
|
| Monoamine Oxidase | 1 | 2016 | 26 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 52 | 0.140 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 31 | 0.140 |
Why?
|
| Cyclopentanes | 1 | 1995 | 15 | 0.140 |
Why?
|
| Glucosamine | 1 | 1995 | 8 | 0.130 |
Why?
|
| Mitochondria | 4 | 2006 | 643 | 0.130 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 61 | 0.130 |
Why?
|
| Student Health Services | 1 | 2015 | 5 | 0.130 |
Why?
|
| RNA-Binding Proteins | 2 | 2014 | 215 | 0.130 |
Why?
|
| Child, Preschool | 2 | 2022 | 3187 | 0.130 |
Why?
|
| RAW 264.7 Cells | 1 | 2015 | 42 | 0.130 |
Why?
|
| Culture | 1 | 2016 | 75 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2018 | 1174 | 0.130 |
Why?
|
| Body Temperature | 1 | 2016 | 116 | 0.130 |
Why?
|
| Health Promotion | 2 | 2015 | 407 | 0.130 |
Why?
|
| Running | 1 | 1995 | 20 | 0.130 |
Why?
|
| RNA | 2 | 2013 | 171 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 88 | 0.130 |
Why?
|
| Sirtuin 1 | 2 | 2013 | 47 | 0.130 |
Why?
|
| Metabolic Diseases | 2 | 2015 | 37 | 0.130 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 189 | 0.130 |
Why?
|
| Physical Endurance | 1 | 1995 | 38 | 0.130 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 226 | 0.130 |
Why?
|
| Hypertension | 7 | 2018 | 1533 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 109 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2015 | 94 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2016 | 156 | 0.130 |
Why?
|
| School Health Services | 1 | 2015 | 72 | 0.130 |
Why?
|
| Chromosome Mapping | 3 | 2008 | 188 | 0.130 |
Why?
|
| Rats, Inbred Strains | 9 | 1989 | 532 | 0.130 |
Why?
|
| Apolipoproteins C | 2 | 2005 | 15 | 0.130 |
Why?
|
| Period Circadian Proteins | 1 | 2014 | 16 | 0.130 |
Why?
|
| HEK293 Cells | 2 | 2013 | 326 | 0.120 |
Why?
|
| Sierra Leone | 3 | 2005 | 5 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2015 | 239 | 0.120 |
Why?
|
| Jamaica | 2 | 2005 | 10 | 0.120 |
Why?
|
| Homocysteine | 1 | 2014 | 26 | 0.120 |
Why?
|
| Bacteria | 1 | 2016 | 193 | 0.120 |
Why?
|
| Motor Activity | 2 | 2015 | 621 | 0.120 |
Why?
|
| Adipose Tissue, White | 1 | 2014 | 7 | 0.120 |
Why?
|
| Adipose Tissue, Brown | 1 | 2014 | 8 | 0.120 |
Why?
|
| Drug Combinations | 2 | 2011 | 304 | 0.120 |
Why?
|
| Health | 1 | 2014 | 26 | 0.120 |
Why?
|
| Xenobiotics | 1 | 2014 | 17 | 0.120 |
Why?
|
| False Negative Reactions | 1 | 2014 | 63 | 0.120 |
Why?
|
| Africa | 3 | 2021 | 41 | 0.120 |
Why?
|
| Exons | 3 | 1998 | 122 | 0.120 |
Why?
|
| Homeostasis | 3 | 2014 | 291 | 0.120 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2013 | 6 | 0.120 |
Why?
|
| Stimulation, Chemical | 1 | 2013 | 57 | 0.120 |
Why?
|
| GTPase-Activating Proteins | 1 | 2013 | 21 | 0.110 |
Why?
|
| 3T3 Cells | 1 | 2013 | 124 | 0.110 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 63 | 0.110 |
Why?
|
| Lod Score | 4 | 2008 | 14 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2013 | 18 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2016 | 322 | 0.110 |
Why?
|
| Europe | 3 | 2021 | 196 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 74 | 0.110 |
Why?
|
| Bariatric Medicine | 1 | 2013 | 1 | 0.110 |
Why?
|
| Acanthosis Nigricans | 1 | 2013 | 4 | 0.110 |
Why?
|
| Behavior, Animal | 1 | 2016 | 470 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2014 | 144 | 0.110 |
Why?
|
| Forearm | 1 | 2013 | 25 | 0.110 |
Why?
|
| Models, Biological | 4 | 2007 | 981 | 0.110 |
Why?
|
| Peroxidases | 1 | 2013 | 28 | 0.110 |
Why?
|
| Muscle Cells | 1 | 2012 | 30 | 0.110 |
Why?
|
| ROC Curve | 1 | 2014 | 392 | 0.110 |
Why?
|
| Immunoassay | 1 | 2012 | 64 | 0.110 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 92 | 0.110 |
Why?
|
| Endocannabinoids | 1 | 2012 | 32 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2017 | 718 | 0.110 |
Why?
|
| Molecular Sequence Data | 6 | 2006 | 1446 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 507 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 106 | 0.110 |
Why?
|
| Hemodynamics | 1 | 1995 | 705 | 0.100 |
Why?
|
| Age Factors | 2 | 2014 | 1860 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 330 | 0.100 |
Why?
|
| Pedigree | 3 | 2011 | 159 | 0.100 |
Why?
|
| Aldehydes | 1 | 2012 | 34 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2015 | 403 | 0.100 |
Why?
|
| Adipogenesis | 1 | 2012 | 17 | 0.100 |
Why?
|
| Population Dynamics | 2 | 2003 | 30 | 0.100 |
Why?
|
| Base Sequence | 5 | 2003 | 1015 | 0.100 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 38 | 0.100 |
Why?
|
| Mutation, Missense | 2 | 2010 | 112 | 0.100 |
Why?
|
| Time | 1 | 2011 | 57 | 0.100 |
Why?
|
| Maze Learning | 1 | 2012 | 138 | 0.100 |
Why?
|
| Lipoprotein Lipase | 1 | 2011 | 5 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 284 | 0.100 |
Why?
|
| Leg | 1 | 2013 | 191 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 434 | 0.100 |
Why?
|
| Rats, Zucker | 2 | 2009 | 10 | 0.100 |
Why?
|
| Intracellular Membranes | 5 | 1996 | 86 | 0.100 |
Why?
|
| Injections, Subcutaneous | 2 | 2022 | 87 | 0.100 |
Why?
|
| Abdominal Fat | 1 | 2011 | 8 | 0.100 |
Why?
|
| Uncoupling Agents | 2 | 2003 | 10 | 0.100 |
Why?
|
| Cardiomyopathies | 1 | 1993 | 167 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1991 | 195 | 0.100 |
Why?
|
| Comorbidity | 4 | 2018 | 1425 | 0.100 |
Why?
|
| Memory Disorders | 1 | 2012 | 111 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 4 | 1997 | 272 | 0.090 |
Why?
|
| NF-kappa B | 2 | 2011 | 432 | 0.090 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 2 | 2014 | 51 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 3 | 2005 | 208 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2008 | 18 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 778 | 0.090 |
Why?
|
| Cystinyl Aminopeptidase | 2 | 2001 | 2 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2008 | 56 | 0.090 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2012 | 18 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 1745 | 0.090 |
Why?
|
| Gene Frequency | 4 | 2013 | 207 | 0.090 |
Why?
|
| Decision Making | 1 | 2013 | 410 | 0.090 |
Why?
|
| Cell Line | 3 | 2013 | 1752 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 86 | 0.090 |
Why?
|
| ATP Binding Cassette Transporter 1 | 2 | 2008 | 13 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2020 | 3703 | 0.090 |
Why?
|
| Proprotein Convertase 9 | 2 | 2020 | 14 | 0.090 |
Why?
|
| Suppression, Genetic | 1 | 1989 | 10 | 0.090 |
Why?
|
| Genetic Linkage | 3 | 1998 | 90 | 0.090 |
Why?
|
| PPAR gamma | 2 | 2012 | 95 | 0.090 |
Why?
|
| Anesthesiologists | 2 | 2019 | 30 | 0.080 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2020 | 62 | 0.080 |
Why?
|
| Alabama | 2 | 2010 | 98 | 0.080 |
Why?
|
| Incretins | 1 | 2008 | 14 | 0.080 |
Why?
|
| Intracellular Space | 1 | 2008 | 42 | 0.080 |
Why?
|
| Food, Formulated | 1 | 2008 | 11 | 0.080 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2008 | 120 | 0.080 |
Why?
|
| Hippocampus | 1 | 2012 | 471 | 0.080 |
Why?
|
| Enteral Nutrition | 1 | 2010 | 157 | 0.080 |
Why?
|
| Premenopause | 1 | 2008 | 57 | 0.080 |
Why?
|
| Telemedicine | 1 | 2017 | 699 | 0.080 |
Why?
|
| Immunoblotting | 3 | 1993 | 254 | 0.080 |
Why?
|
| Anthropology, Physical | 2 | 2005 | 2 | 0.080 |
Why?
|
| Family Health | 1 | 2008 | 83 | 0.080 |
Why?
|
| Microsomes | 3 | 2001 | 31 | 0.080 |
Why?
|
| Lymphocytes | 2 | 2004 | 228 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2010 | 402 | 0.080 |
Why?
|
| DNA Primers | 4 | 2004 | 302 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 710 | 0.080 |
Why?
|
| Myocardium | 2 | 1997 | 1204 | 0.080 |
Why?
|
| Risperidone | 1 | 2008 | 48 | 0.080 |
Why?
|
| Lac Operon | 1 | 2007 | 54 | 0.080 |
Why?
|
| Body Constitution | 2 | 2006 | 24 | 0.070 |
Why?
|
| Benzodiazepines | 1 | 2008 | 130 | 0.070 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2006 | 6 | 0.070 |
Why?
|
| Epididymis | 3 | 1996 | 10 | 0.070 |
Why?
|
| Colesevelam Hydrochloride | 3 | 2011 | 6 | 0.070 |
Why?
|
| Prevalence | 3 | 2017 | 1609 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 25 | 0.070 |
Why?
|
| Schizophrenia | 1 | 2008 | 206 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 371 | 0.070 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 85 | 0.070 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2005 | 3 | 0.070 |
Why?
|
| Peroxisome Proliferators | 1 | 2005 | 5 | 0.070 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2005 | 7 | 0.070 |
Why?
|
| Physical Fitness | 2 | 2019 | 117 | 0.070 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 31 | 0.070 |
Why?
|
| Sterol Esterase | 1 | 2005 | 5 | 0.070 |
Why?
|
| Response Elements | 1 | 2005 | 29 | 0.070 |
Why?
|
| Metabolomics | 2 | 2019 | 28 | 0.070 |
Why?
|
| Congresses as Topic | 2 | 2017 | 85 | 0.070 |
Why?
|
| Pacific States | 1 | 2005 | 1 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 320 | 0.070 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2005 | 6 | 0.060 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2005 | 9 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2013 | 1615 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 223 | 0.060 |
Why?
|
| Biological Transport, Active | 2 | 1998 | 49 | 0.060 |
Why?
|
| Ligands | 1 | 2006 | 317 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 498 | 0.060 |
Why?
|
| Glycolysis | 2 | 1995 | 79 | 0.060 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Glucose Transporter Type 5 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 563 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2006 | 1082 | 0.060 |
Why?
|
| Food | 1 | 2004 | 52 | 0.060 |
Why?
|
| Immunity | 1 | 2004 | 67 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2004 | 397 | 0.060 |
Why?
|
| Neurons | 1 | 1989 | 881 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2013 | 59 | 0.060 |
Why?
|
| Electron Transport | 1 | 2003 | 37 | 0.050 |
Why?
|
| Prekallikrein | 1 | 2003 | 66 | 0.050 |
Why?
|
| California | 1 | 2003 | 99 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2003 | 87 | 0.050 |
Why?
|
| Fructosamine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2003 | 50 | 0.050 |
Why?
|
| Stroke | 1 | 2015 | 2162 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 210 | 0.050 |
Why?
|
| Causality | 1 | 2023 | 81 | 0.050 |
Why?
|
| New York | 1 | 2023 | 223 | 0.050 |
Why?
|
| Mother-Child Relations | 1 | 2022 | 43 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 742 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 20 | 0.050 |
Why?
|
| Health Behavior | 2 | 2020 | 458 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2012 | 103 | 0.050 |
Why?
|
| Cholesterol, HDL | 2 | 2017 | 112 | 0.050 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 2013 | 7 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 1997 | 562 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2002 | 411 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2006 | 546 | 0.050 |
Why?
|
| Secondary Prevention | 2 | 2014 | 291 | 0.050 |
Why?
|
| Y Chromosome | 1 | 2001 | 5 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2011 | 219 | 0.050 |
Why?
|
| Syndrome | 2 | 1999 | 255 | 0.050 |
Why?
|
| Linoleic Acid | 1 | 2020 | 13 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2020 | 8 | 0.050 |
Why?
|
| Lipoxygenase | 1 | 2020 | 13 | 0.050 |
Why?
|
| Prolactin | 1 | 2000 | 61 | 0.050 |
Why?
|
| Capillaries | 1 | 2021 | 105 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 134 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 1998 | 32 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2022 | 567 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2020 | 62 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 1998 | 420 | 0.050 |
Why?
|
| Blotting, Northern | 2 | 1991 | 189 | 0.040 |
Why?
|
| Christianity | 1 | 2000 | 16 | 0.040 |
Why?
|
| Pericytes | 1 | 2021 | 81 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2011 | 167 | 0.040 |
Why?
|
| Anorexia Nervosa | 1 | 2000 | 52 | 0.040 |
Why?
|
| Postprandial Period | 2 | 2010 | 21 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2022 | 880 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 532 | 0.040 |
Why?
|
| Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) | 1 | 1999 | 1 | 0.040 |
Why?
|
| Biotechnology | 1 | 1999 | 34 | 0.040 |
Why?
|
| rab4 GTP-Binding Proteins | 1 | 1998 | 2 | 0.040 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 1998 | 3 | 0.040 |
Why?
|
| Tissue Distribution | 3 | 1997 | 282 | 0.040 |
Why?
|
| Homozygote | 1 | 1999 | 119 | 0.040 |
Why?
|
| Codon, Terminator | 1 | 1998 | 6 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2000 | 291 | 0.040 |
Why?
|
| Omentum | 3 | 1993 | 18 | 0.040 |
Why?
|
| Cholesterol Esters | 1 | 1998 | 26 | 0.040 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 1998 | 13 | 0.040 |
Why?
|
| Genetic Carrier Screening | 1 | 1998 | 25 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2010 | 260 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2011 | 137 | 0.040 |
Why?
|
| Apolipoprotein A-I | 1 | 1998 | 29 | 0.040 |
Why?
|
| Apoptosis | 2 | 2018 | 1641 | 0.040 |
Why?
|
| Plant Proteins | 1 | 1998 | 48 | 0.040 |
Why?
|
| Prothrombin | 1 | 1978 | 12 | 0.040 |
Why?
|
| Vitamin K Deficiency | 1 | 1978 | 2 | 0.040 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1998 | 36 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 497 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 91 | 0.040 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2018 | 9 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 1998 | 93 | 0.040 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2018 | 20 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2018 | 73 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2018 | 38 | 0.040 |
Why?
|
| Protein Precursors | 1 | 1978 | 105 | 0.040 |
Why?
|
| Venezuela | 1 | 2017 | 6 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 69 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 1997 | 41 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 137 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1999 | 282 | 0.040 |
Why?
|
| Tunica Media | 2 | 2008 | 33 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 5 | 0.040 |
Why?
|
| World Health Organization | 1 | 2017 | 53 | 0.040 |
Why?
|
| Triazines | 1 | 2018 | 48 | 0.040 |
Why?
|
| Glucokinase | 1 | 1997 | 6 | 0.040 |
Why?
|
| RNA, Transfer, Leu | 1 | 1997 | 5 | 0.040 |
Why?
|
| Tunica Intima | 2 | 2008 | 59 | 0.040 |
Why?
|
| Microvascular Angina | 1 | 1997 | 2 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 82 | 0.040 |
Why?
|
| Protein Conformation | 1 | 1998 | 362 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 1997 | 11 | 0.040 |
Why?
|
| NADPH-Ferrihemoprotein Reductase | 1 | 2017 | 3 | 0.040 |
Why?
|
| Body Temperature Regulation | 1 | 1997 | 29 | 0.040 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2017 | 5 | 0.040 |
Why?
|
| Glutathione Reductase | 1 | 2017 | 17 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2017 | 12 | 0.040 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2016 | 2 | 0.040 |
Why?
|
| Electronic Mail | 1 | 2017 | 29 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 1997 | 40 | 0.040 |
Why?
|
| Catalase | 1 | 2017 | 85 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2018 | 312 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2017 | 119 | 0.040 |
Why?
|
| Veterans Health | 1 | 2017 | 62 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 1996 | 34 | 0.030 |
Why?
|
| Costa Rica | 1 | 2016 | 6 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 977 | 0.030 |
Why?
|
| Latin America | 1 | 2016 | 19 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 149 | 0.030 |
Why?
|
| Telephone | 1 | 2017 | 160 | 0.030 |
Why?
|
| Brefeldin A | 1 | 1995 | 11 | 0.030 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1995 | 32 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 248 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 68 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1997 | 328 | 0.030 |
Why?
|
| Sleep | 1 | 2018 | 263 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2010 | 251 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 1995 | 75 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 314 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1995 | 133 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 307 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 168 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1995 | 334 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 19 | 0.030 |
Why?
|
| Apolipoprotein C-III | 2 | 2005 | 12 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1995 | 276 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 1995 | 179 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 132 | 0.030 |
Why?
|
| Hyperhomocysteinemia | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cell Compartmentation | 2 | 1991 | 41 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2010 | 219 | 0.030 |
Why?
|
| Glucose Transporter Type 2 | 1 | 1994 | 2 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 277 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2014 | 36 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1993 | 50 | 0.030 |
Why?
|
| Leucine | 1 | 1994 | 41 | 0.030 |
Why?
|
| Streptozocin | 1 | 1993 | 34 | 0.030 |
Why?
|
| Phosphorylation | 3 | 2011 | 1200 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2013 | 14 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 1993 | 76 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 1994 | 219 | 0.030 |
Why?
|
| Patient Safety | 1 | 2015 | 202 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2013 | 18 | 0.030 |
Why?
|
| Sarcolemma | 1 | 1993 | 16 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2013 | 60 | 0.030 |
Why?
|
| Cesarean Section | 1 | 1993 | 101 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1994 | 181 | 0.030 |
Why?
|
| Heart Rate | 1 | 1995 | 568 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2013 | 43 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2013 | 89 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2014 | 205 | 0.030 |
Why?
|
| Decision Trees | 1 | 2013 | 74 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1341 | 0.030 |
Why?
|
| Stroke Volume | 1 | 1995 | 586 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 2550 | 0.030 |
Why?
|
| Benchmarking | 1 | 2013 | 91 | 0.030 |
Why?
|
| Self Report | 1 | 2014 | 370 | 0.030 |
Why?
|
| Fatty Liver | 1 | 2013 | 97 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2013 | 168 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2013 | 233 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 8 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2012 | 6 | 0.030 |
Why?
|
| Checklist | 1 | 2013 | 76 | 0.030 |
Why?
|
| Cytochalasin B | 2 | 1989 | 7 | 0.030 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1992 | 40 | 0.030 |
Why?
|
| Pancreas | 1 | 2013 | 225 | 0.030 |
Why?
|
| Acetylcarnitine | 1 | 2010 | 1 | 0.020 |
Why?
|
| Tricarboxylic Acids | 1 | 2010 | 3 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 191 | 0.020 |
Why?
|
| Calcitriol | 1 | 1991 | 106 | 0.020 |
Why?
|
| Bone Density | 1 | 2012 | 159 | 0.020 |
Why?
|
| Cell Division | 1 | 1992 | 541 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 266 | 0.020 |
Why?
|
| Fear | 1 | 2012 | 239 | 0.020 |
Why?
|
| Memory | 1 | 2012 | 214 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 214 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 383 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2010 | 51 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2010 | 32 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 438 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 63 | 0.020 |
Why?
|
| Weight Gain | 1 | 2010 | 135 | 0.020 |
Why?
|
| Second Messenger Systems | 1 | 1989 | 53 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 848 | 0.020 |
Why?
|
| Plasmids | 1 | 2010 | 258 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1549 | 0.020 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2008 | 6 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 592 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2018 | 1032 | 0.020 |
Why?
|
| Digestion | 1 | 2008 | 6 | 0.020 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2008 | 8 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 1 | 2008 | 20 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1989 | 379 | 0.020 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 8 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2008 | 110 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2008 | 201 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 1989 | 368 | 0.020 |
Why?
|
| Vanadium | 1 | 1987 | 5 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 1998 | 40 | 0.020 |
Why?
|
| Endocytosis | 1 | 1987 | 113 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2008 | 157 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2006 | 72 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1987 | 260 | 0.020 |
Why?
|
| Melanocyte-Stimulating Hormones | 1 | 2006 | 3 | 0.020 |
Why?
|
| Receptor, Melanocortin, Type 3 | 1 | 2006 | 2 | 0.020 |
Why?
|
| alpha-MSH | 1 | 2006 | 7 | 0.020 |
Why?
|
| Amino Acids, Aromatic | 1 | 2006 | 7 | 0.020 |
Why?
|
| Receptors, Peptide | 1 | 2006 | 32 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 1449 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2006 | 204 | 0.020 |
Why?
|
| Calcium | 1 | 1989 | 929 | 0.020 |
Why?
|
| Spermine | 1 | 1985 | 49 | 0.020 |
Why?
|
| Insulin Infusion Systems | 1 | 1985 | 27 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 322 | 0.020 |
Why?
|
| Feedback | 1 | 1985 | 90 | 0.020 |
Why?
|
| Microcirculation | 1 | 2005 | 77 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 448 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2005 | 104 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2004 | 56 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2006 | 453 | 0.010 |
Why?
|
| Lipoproteins, IDL | 1 | 2003 | 8 | 0.010 |
Why?
|
| Guanine | 1 | 2003 | 21 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 2003 | 17 | 0.010 |
Why?
|
| Adenine | 1 | 2003 | 46 | 0.010 |
Why?
|
| Kininogen, High-Molecular-Weight | 1 | 2003 | 23 | 0.010 |
Why?
|
| Factor XII | 1 | 2003 | 96 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 243 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 1027 | 0.010 |
Why?
|
| Kinins | 1 | 2003 | 109 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 2798 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 272 | 0.010 |
Why?
|
| Agouti-Related Protein | 1 | 2001 | 1 | 0.010 |
Why?
|
| Kallikreins | 1 | 2003 | 323 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2006 | 617 | 0.010 |
Why?
|
| Cytosol | 2 | 1991 | 123 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1046 | 0.010 |
Why?
|
| Carbohydrates | 1 | 1999 | 57 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 219 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1991 | 765 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1998 | 28 | 0.010 |
Why?
|
| Vitamin K 1 | 1 | 1978 | 1 | 0.010 |
Why?
|
| Brain | 1 | 1989 | 2176 | 0.010 |
Why?
|
| Community Health Services | 1 | 2000 | 141 | 0.010 |
Why?
|
| Vitamin K | 1 | 1978 | 14 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 172 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1998 | 15 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1998 | 23 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 144 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1998 | 18 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2324 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 521 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 179 | 0.010 |
Why?
|
| Arizona | 1 | 1997 | 9 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1997 | 10 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2000 | 502 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1997 | 65 | 0.010 |
Why?
|
| Research | 1 | 1998 | 214 | 0.010 |
Why?
|
| Chickens | 1 | 1978 | 232 | 0.010 |
Why?
|
| Actin Cytoskeleton | 1 | 1997 | 37 | 0.010 |
Why?
|
| Pinocytosis | 1 | 1996 | 2 | 0.010 |
Why?
|
| Silver Staining | 1 | 1996 | 11 | 0.010 |
Why?
|
| Dextrans | 1 | 1996 | 33 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1996 | 50 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 1997 | 109 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1988 | 618 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 351 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1996 | 155 | 0.010 |
Why?
|
| Solvents | 1 | 1996 | 109 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1996 | 149 | 0.010 |
Why?
|
| Epithelium | 1 | 1994 | 172 | 0.010 |
Why?
|
| Sodium | 1 | 1994 | 161 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1993 | 18 | 0.010 |
Why?
|
| Photochemistry | 1 | 1993 | 46 | 0.010 |
Why?
|
| Cell Separation | 1 | 1993 | 132 | 0.010 |
Why?
|
| Affinity Labels | 1 | 1993 | 66 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1996 | 511 | 0.010 |
Why?
|
| Liposomes | 1 | 1993 | 107 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1993 | 137 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1991 | 57 | 0.010 |
Why?
|
| Receptors, Calcitriol | 1 | 1991 | 49 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1991 | 121 | 0.010 |
Why?
|
| Infant | 1 | 1997 | 2891 | 0.010 |
Why?
|
| Ionomycin | 1 | 1989 | 24 | 0.010 |
Why?
|
| Potassium | 1 | 1989 | 168 | 0.010 |
Why?
|
| Vanadates | 1 | 1987 | 12 | 0.000 |
Why?
|
| Chloroquine | 1 | 1987 | 21 | 0.000 |
Why?
|
| Half-Life | 1 | 1987 | 96 | 0.000 |
Why?
|
| Sphingosine | 1 | 1989 | 315 | 0.000 |
Why?
|
| Immunologic Tests | 1 | 1987 | 9 | 0.000 |
Why?
|
| Isoelectric Focusing | 1 | 1987 | 42 | 0.000 |
Why?
|
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 1 | 1987 | 19 | 0.000 |
Why?
|
| Glycoside Hydrolases | 1 | 1987 | 25 | 0.000 |
Why?
|
| Proinsulin | 1 | 1985 | 3 | 0.000 |
Why?
|